Screener
Kymera Therapeutics KYMR Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense): | ||||
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
| Interest and other expense | (81) | (108) | (141) | (180) |
| Total other income: | 14,396 | 7,943 | 29,318 | 16,788 |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on marketable securities | (2,963) | 337 | (8,957) | 1,764 |
| Total comprehensive loss | $(64,174) | $(76,277) | $(139,402) | $(140,431) |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's other income (expense)?
- Kymera Therapeutics (KYMR) reported other income (expense) of $14.4M in Q2 2026.
- How has Kymera Therapeutics's other income (expense) changed year-over-year?
- Kymera Therapeutics's other income (expense) increased by 81.2% year-over-year, from $7.94M to $14.4M.
- What is the long-term trend for Kymera Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other income (expense) has grown at a 232.0% compound annual growth rate (CAGR), from $313K to $38.05M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Kymera Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude